Zobrazeno 1 - 10
of 366
pro vyhledávání: '"Stephen J Greene"'
Autor:
Abraish Ali, Asad Ali Siddiqui, Izza Shahid, Harriette G. C. Van Spall, Stephen J. Greene, Marat Fudim, Muhammad Shahzeb Khan
Publikováno v:
The Egyptian Heart Journal, Vol 76, Iss 1, Pp 1-12 (2024)
Abstract Background Functional health status is increasingly being recognized as a viable endpoint in heart failure (HF) trials. We sought to assess its prognostic impact and relationship with traditional clinical outcomes in patients with HF. Method
Externí odkaz:
https://doaj.org/article/482f4a449e7346da903cb2cb6d03d097
Autor:
Stephen J. Greene, Hanna K. Gaggin, Mo Zhou, Lori D. Bash, Dominik Lautsch, Laurence Djatche, Yan Song, James Signorovitch, Andra S. Stevenson, Robert O. Blaustein, Javed Butler
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 1932-1946 (2024)
Abstract Aims Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease‐modifying therapy. CHART‐HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and wi
Externí odkaz:
https://doaj.org/article/fd262287325f47009eb6cbad8faee8cd
Autor:
Suzanne Oskouie, MD, Ambarish Pandey, MD, MSCS, Andrew J. Sauer, MD, Stephen J. Greene, MD, Wilfried Mullens, MD, PhD, Muhammad Shahzeb Khan, MD, MSc, Kieran L. Quinn, MD, PhD, Jennifer E. Ho, MD, Nancy M. Albert, PhD, Harriette GC. Van Spall, MD, MPH
Publikováno v:
JACC: Advances, Vol 3, Iss 9, Pp 101131- (2024)
Heart failure (HF) is a leading cause of hospitalization in older adults. Patients are at high risk of readmission and death following hospitalization for HF. There is no standard approach of health care delivery during the hospital-to-home transitio
Externí odkaz:
https://doaj.org/article/76cf31bffd3d4d7f8467f0476677e04d
Autor:
Pascal R. D. Clephas, Jishnu Malgie, Jeroen Schaap, Stefan Koudstaal, Mireille Emans, Gerard C. M. Linssen, Grytsje A. deBoer, Loek vanHeerebeek, C. Jan Willem Borleffs, Olivier C. Manintveld, Vanessa vanEmpel, Sandra vanWijk, Mieke van denHeuvel, Carlos daFonseca, Kevin Damman, Jan vanRamshorst, Roland vanKimmenade, Arjen R. T. van deVen, René A. Tio, Dennis vanVeghel, Folkert W. Asselbergs, Rudolf A. deBoer, Peter van derMeer, Stephen J. Greene, Hans‐Peter Brunner‐La Rocca, Jasper J. Brugts
Publikováno v:
ESC Heart Failure, Vol 11, Iss 1, Pp 550-559 (2024)
Abstract Aims Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline‐directed medical therapy (GDMT) rega
Externí odkaz:
https://doaj.org/article/76fc22140ff146f4acc31d2d5d84e800
Autor:
Hanna K. Gaggin, Stephen J. Greene, Mo Zhou, Dominik Lautsch, Lori D. Bash, Laurence Djatche, Yan Song, James Signorovitch, Andra S. Stevenson, Robert O. Blaustein, Javed Butler
Publikováno v:
International Journal of Cardiology. Cardiovascular Risk and Prevention, Vol 21, Iss , Pp 200278- (2024)
Background: Based on available data from randomized clinical trials, patients with heart failure with reduced ejection fraction (HFrEF) and worsening HF events (WHFE) have substantial disease burden and poor outcomes. WHFE clinical outcome data in no
Externí odkaz:
https://doaj.org/article/d7dad2a515474427b5c9f5664625db9e
Autor:
Abdul Mannan Khan Minhas, Jakrin Kewcharoen, Michael E. Hall, Haider J. Warraich, Stephen J. Greene, Michael D. Shapiro, Erin D. Michos, Andrew J. Sauer, Dmitry Abramov
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 2 (2024)
Background There are limited data on substance use (SU) and cardiovascular disease (CVD)–related mortality trends in the United States. We aimed to evaluate SU+CVD–related deaths in the United States using the Centers for Disease Control and Prev
Externí odkaz:
https://doaj.org/article/b197334e08c940928ea6042ffe2ab016
Autor:
Tiew‐Hwa Katherine Teng, Wan Ting Tay, Wouter Ouwerkerk, Jasper Tromp, A. Mark Richards, Greg Gamble, Stephen J. Greene, Kai‐Hang Yiu, Katrina Poppe, Lieng Hsi Ling, Mayanna Lund, David Sim, Gerard Devlin, Seet Yoong Loh, Richard Troughton, Qing‐wen Ren, Fazlur Jaufeerally, Shao Guang Sheldon Lee, Ru San Tan, Dinna Kar Nee Soon, Gerald Leong, Hean Yee Ong, Daniel P.S. Yeo, Carolyn S.P. Lam, Rob N. Doughty
Publikováno v:
ESC Heart Failure, Vol 10, Iss 2, Pp 1280-1293 (2023)
Abstract Aims We investigated titration patterns of angiotensin‐converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs) and beta‐blockers, quality of life (QoL) over 6 months, and associated 1 year outcome [all‐cause mortality
Externí odkaz:
https://doaj.org/article/e5c66e06824e45f2ae879bc7a624007f
Autor:
Yuhui Zhang, Chuanyu Gao, Stephen J. Greene, Barry H. Greenberg, Javed Butler, Jing Yu, Zhaofen Zheng, Genshan Ma, Lian Wang, Ping Yang, Xiaoping Ji, Dingli Xu, Jiang Wang, Yao Zhang, Ying Liu, Yan Zhao, Hong Qi, Mei Zhai, Jiayu Feng, Yan Huang, Qiong Zhou, Jian Zhang
Publikováno v:
ESC Heart Failure, Vol 10, Iss 1, Pp 342-352 (2023)
Abstract Aims Heart failure (HF) remains a major public health problem with increasing prevalence in China. This study evaluated the clinical performance and quality measures for HF management to identify gaps in the standardization of care for patie
Externí odkaz:
https://doaj.org/article/8ff2d9b28e5143ec9e21c43142273641
Autor:
Josephine Harrington, Jie‐Lena Sun, Gregg C. Fonarow, Stephen B. Heitner, Punag H. Divanji, Gary Binder, Larry A. Allen, Brooke Alhanti, Clyde W. Yancy, Nancy M. Albert, Adam D. DeVore, G. Michael Felker, Stephen J. Greene
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 10 (2023)
Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated with these patients in
Externí odkaz:
https://doaj.org/article/1562516935a04e21a697a6a639dfaab1
Autor:
Muhammad Shariq Usman, Muhammad Shahzeb Khan, Gregg C. Fonarow, Stephen J. Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos Filippatos, Andrew J. Stewart Coats, Stefan D. Anker, Javed Butler
Publikováno v:
ESC Heart Failure, Vol 9, Iss 2, Pp 885-893 (2022)
Abstract Aims Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI). Methods and results Fragil
Externí odkaz:
https://doaj.org/article/0f8e31a4617d400987e8af5bf3e7a28a